TABLE 1.
Estimated vaccination coverage with selected vaccines and doses among adolescents aged 13–17* years, by age at interview — National Immunization Survey–Teen (NIS-Teen), United States, 2014
| Vaccine | Age at interview (yrs) (2014) | Total (adolescents aged 13–17 yrs) | |||||
|---|---|---|---|---|---|---|---|
|
|
|
||||||
| 13 (n = 4,292) % (95% CI) | 14 (n = 4,329) % (95% CI) | 15 (n = 4,143) % (95% CI) | 16 (n = 4,215) % (95% CI) | 17 (n = 3,848) % (95% CI) | 2014 (n = 20,827) % (95% CI) | 2013† (n = 18,948) % (95% CI) | |
| Tdap§ ≥1 dose | 87.5 (±2.1) | 89.1 (±1.6) | 88.3 (±1.9) | 86.9 (±2.1) | 86.3 (±2.0) | 87.6 (±0.9)¶ | 84.7 (±1.0) |
| MenACWY** ≥1 dose | 78.0 (±2.5) | 81.0 (±2.1) | 79.2 (±2.5) | 79.4 (±2.5) | 78.8 (±2.5) | 79.3 (±1.1)¶ | 76.6 (±1.1) |
| MenACWY ≥2 doses | — | — | — | — | 28.5 (±2.8)†† | — | — |
| HPV§§ vaccine coverage by doses | |||||||
| Females | |||||||
| ≥1 dose | 51.1 (±4.1) | 56.6 (±3.9) | 61.0 (±4.3)¶¶ | 64.4 (±4.1)¶¶ | 66.5 (±4.4)¶¶ | 60.0 (±1.9)¶ | 56.7 (±1.9) |
| ≥2 doses | 40.1 (±4.0) | 46.4 (±4.0)¶¶ | 51.6 (±4.3)¶¶ | 55.7 (±4.2)¶¶ | 57.6 (±4.7)¶¶ | 50.3 (±1.9)¶ | 46.9 (±1.9) |
| ≥3 doses | 26.2 (±3.6) | 35.9 (±3.9)¶¶ | 41.2 (±4.2)¶¶ | 43.8 (±4.1)¶¶ | 51.0 (±4.7)¶¶ | 39.7 (±1.9)¶ | 36.8 (±1.9) |
| Males | |||||||
| ≥1 dose | 38.9 (±4.2) | 42.6 (±4.0) | 45.7 (±4.1)¶¶ | 40.0 (±4.0) | 41.8 (±4.1) | 41.7 (±1.8)¶ | 33.6 (±1.8) |
| ≥2 doses | 27.1 (±3.9) | 30.9 (±3.8) | 35.8 (±4.1)¶¶ | 31.2 (±3.8) | 32.6 (±4.0) | 31.4 (±1.7)¶ | 22.6 (±1.6) |
| ≥3 doses | 16.2 (±3.3) | 20.9 (±3.5) | 24.9 (±4.0)¶¶ | 22.9 (±3.5)¶¶ | 23.3 (±3.7)¶¶ | 21.6 (±1.6)¶ | 13.4 (±1.3) |
| HPV vaccine 3-dose series completion *** | |||||||
| Females | 56.1 (±6.3) | 66.8 (±5.2)¶¶ | 70.3 (±5.0)¶¶ | 70.8 (±5.2)¶¶ | 78.3 (±5.4)¶¶ | 69.3 (±2.4) | 69.8 (±2.5) |
| Males | 47.1 (±7.6) | 56.6 (±6.6) | 58.1 (±6.6)¶¶ | 64.7 (±6.1)¶¶ | 61.7 (±6.6)¶¶ | 57.8 (±3.0)¶ | 48.2 (±3.9) |
| MMR ≥2 doses | 90.2 (±1.8) | 91.1 (±1.6) | 91.2 (±1.6) | 90.2 (±1.9) | 90.9 (±1.6) | 90.7 (±0.8) | 89.6 (±0.9) |
| HepB ≥3 doses | 91.3 (±1.8) | 91.7 (±1.5) | 92.5 (±1.4) | 90.2 (±2.0) | 91.4 (±1.5) | 91.4 (±0.7) | 91.3 (±0.8) |
| Varicella vaccine | |||||||
| History of varicella††† | 13.7 (±2.0) | 17.8 (±2.4)¶¶ | 20.2 (±2.4)¶¶ | 24.2 (±2.6)¶¶ | 29.3 (±2.8)¶¶ | 21.0 (±1.1)¶ | 25.2 (±1.1) |
| Among adolescents with no history of varicella | |||||||
| ≥1 dose vaccine | 95.6 (±1.3) | 95.7 (±1.2) | 95.6 (±1.1) | 95.1 (±1.2) | 93.6 (±1.5) | 95.2 (±0.6)¶ | 93.5 (±0.9) |
| ≥2 doses vaccine | 83.1 (±2.4) | 81.9 (±2.3) | 81.1 (±2.6) | 81.0 (±2.6) | 77.1 (±3.1)¶¶ | 81.0 (±1.2)¶ | 76.8 (±1.3) |
| History of varicella or received ≥2 doses varicella vaccine | 85.4 (±2.1) | 85.1 (±1.9) | 85.0 (±2.1) | 85.6 (±2.0) | 83.8 (±2.3) | 85.0 (±0.9)¶ | 82.7 (±1.0) |
Abbreviations: CI = confidence interval; Tdap = tetanus-diphtheria-acellular pertussis vaccine; MenACWY = meningococcal conjugate vaccine; HPV = human papillomavirus; MMR = measles, mumps, and rubella vaccine; HepB = hepatitis B vaccine.
Adolescents (N = 20,827) in the 2014 NIS-Teen were born during the period January 1996-February 2002.
Revised estimates for overall NIS-Teen data for 2013 were provided as a comparison to overall 2014 NIS-Teen data. A revised adequate provider data definition was implemented in 2014 NIS-Teen, and estimates might not be directly comparable to those previously published. For comparative purposes, 2013 estimates included in this table have been calculated by retrospectively applying the revised adequate provider data definition to 2013 NIS-Teen data and, as a result, will differ from those previously published.
Includes percentages receiving Tdap at or after age 10 years.
Statistically significant difference (p<0.05) compared with 2013 NIS-Teen estimates.
Includes percentages receiving MenACWY or meningococcal-unknown type vaccine.
≥2 doses of MenACWY or meningococcal-unknown type vaccine. Calculated only among adolescents who were aged 17 years at time of interview. Does not include adolescents who received 1 dose of MenACWY vaccine at or after age 16 years.
HPV vaccine, either quadrivalent (4vHPV) or bivalent (2vHPV). Although only 4vHPV was recommended for use in males in 2014, some might have received 2vHPV. In 2014 data, percentage was reported among 10,084 females and 10,743 males. In 2013 data, percentage was reported among 9,042 females and 9,906 males. Some adolescents might have received more than the 3 recommended HPV vaccine doses.
Statistically significant difference (p<0.05) in estimated vaccination coverage by age; reference group was adolescents aged 13 years.
The completion rate for the 3-dose HPV vaccination series represents the percentage of adolescents who received ≥3 HPV doses among those who had ≥1 HPV vaccine dose with at least 24 weeks between the first dose and the interview date. The denominator for this calculation was limited to 5,703 females and 3,935 males in 2014 and 4,704 females and 2,623 males in 2013 who received their first HPV dose and had enough time to receive the third HPV dose.
By parent/guardian report or provider records.